Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved tucatinib (Tukysa) combined with trastuzumab and pertuzumab as a front-line maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer. Data from the phase 3 HER2CLIMB-05 trial showed the chemotherapy-free regimen cut the risk of disease progression or death by 35.9%, extending median PFS from 16.3 to 24.9 months.
The FDA has approved tucatinib (Tukysa, Pfizer) in combination with trastuzumab and pertuzumab as maintenance therapy for adults with unresectable locally advanced or metastatic HER2-positive breast cancer following induction treatment — marking a significant move into the front-line setting for the oral tyrosine kinase inhibitor, which was previously approved only as a second-line option.
The approval is backed by the randomized, double-blind, phase 3 HER2CLIMB-05 trial enrolling 654 patients who showed no disease progression after 4–8 cycles of induction therapy with trastuzumab, pertuzumab, and a taxane. Patients received either tucatinib 300 mg or placebo twice daily alongside trastuzumab and pertuzumab until progression or unacceptable toxicity. The regimen works by targeting HER2 signaling both intracellularly (tucatinib) and extracellularly (trastuzumab/pertuzumab), offering a chemotherapy-free maintenance approach.
By the Numbers:
Why it matters: This approval offers oncologists a chemotherapy-free maintenance strategy that meaningfully prolongs disease control in HER2+ metastatic breast cancer — a population where progression remains common despite initial response to therapy. Overall survival data are still maturing.
